Galmed Pharmaceuticals Ltd. (GPH.F)

0,3800 +0,0280 (+7,95%) Ab 08:02AM CEST. Markt geöffnet.

Galmed Pharmaceuticals Ltd.

16 Tiomkin Street
Tel Aviv 6578317
Israel
972 3 693 8448
https://www.galmedpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 3

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Allen Baharaff	Co-Founder, President, CEO & Chairman	903,7k	N/A	1965
Mr. Doron Cohen	Chief Financial Officer	228,66k	N/A	1967
Mr. Guy Nehemya	COO & Data Protection Officer	266,82k	N/A	1985
Mr. Yohai Stenzler CPA	Chief Accounting Officer	270,11k	N/A	1983
Dr. Liat Hayardeny	Chief Scientific Officer	44,56k	N/A	1967
Ms. Yael Hollander	Vice President of Legal Affairs & Strategy	124,76k	N/A	1983
Ms. Shani Ganon	Human Resources Manager	N/A	N/A	N/A
Dr. Tali Gorfine	Medical Consultant	188,49k	N/A	1970

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Corporate Governance

Galmed Pharmaceuticals Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.